ArticleInfection2023
Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study.
Article in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Research focus and emerging trends of the gut microbiome and infant: a bibliometric analysis from 2004 to 2024.Frontiers in microbiology · 2024Pooled it
- Time to rethink prevention of neonatal group B streptococcal disease.Seminars in immunopathology · 2026Review
- Bacterial targeting of the neutrophil inhibitory receptor LILRB3 to evade antibody immunity.Nature communications · 2026Article
- Gene Factors and Serotypes Related to Polysaccharide and Protein-Based Candidate Vaccines AmongCurrent issues in molecular biology · 2026Article
- Atypical detection of group B Streptococcus ST - 17 clone from a diabetic patient with necrotising fasciitis: A case report.IDCases · 2026Article
- A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction.Nature communications · 2025Article
- The virulence regulator CovR boosts CRISPR-Cas9 immunity in Group B Streptococcus.Nature communications · 2025Article
- Group B Streptococcus (GBS) Carriage in Pregnant Women: Possible Emergence of Rare Serotypes and Antibiotic Resistance in Neonatal Disease.Microorganisms · 2025Article
- Article
- Genetic Mechanisms of Antimicrobial Non-Susceptibility to Novel Fluoroquinolone Delafloxacin Among Bulgarian Clinical Isolates ofCurrent issues in molecular biology · 2025Article
- Group B Streptococcus maternal colonization and neonatal sepsis in Belgium between 2012 and 2021: a description of the epidemiological situation and identification of risk factors.BMC pregnancy and childbirth · 2025Article
- Group B streptococcal infections in pregnancy and early life.Clinical microbiology reviews · 2025Review
- Article
- Mechanisms and Manifestations of Group B Streptococcus Meningitis in Newborns.Journal of the Pediatric Infectious Diseases Society · 2025Review
- Profiling the response of individual gut microbes to free fatty acids (FFAs) found in human milk.Journal of functional foods · 2025Article
- Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study.Infection · 2025Article
- Article
- Group B streptococcus in pregnant women and neonates in Africa: a scoping review.BMJ public health · 2025Article
- Role of the SaeRS Two-Component Regulatory System in Group BMicroorganisms · 2024Article
- Performance Evaluation of NovaplexMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 8 countries.
Funding
Abstract
purposeGroup B streptococcus (GBS) remains a leading cause of invasive disease, mainly sepsis and meningitis, in infants < 3 months of age and of mortality among neonates. This study, a major component of the European DEVANI project (Design of a Vaccine Against Neonatal Infections) describes clinical and important microbiological characteristics of neonatal GBS diseases. It quantifies the rate of antenatal screening and intrapartum antibiotic prophylaxis among cases and identifies risk factors associated with an adverse outcome.
methodsClinical and microbiological data from 153 invasive neonatal cases (82 early-onset [EOD], 71 late-onset disease [LOD] cases) were collected in eight European countries from mid-2008 to end-2010.
resultsRespiratory distress was the most frequent clinical sign at onset of EOD, while meningitis is found in > 30% of LOD. The study revealed that 59% of mothers of EOD cases had not received antenatal screening, whilst GBS was detected in 48.5% of screened cases. Meningitis was associated with an adverse outcome in LOD cases, while prematurity and the presence of cardiocirculatory symptoms were associated with an adverse outcome in EOD cases. Capsular-polysaccharide type III was the most frequent in both EOD and LOD cases with regional differences in the clonal complex distribution.
conclusionsStandardizing recommendations related to neonatal GBS disease and increasing compliance might improve clinical care and the prevention of GBS EOD. But even full adherence to antenatal screening would miss a relevant number of EOD cases, thus, the most promising prophylactic approach against GBS EOD and LOD would be a vaccine for maternal immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.